Clarissa Desjardins, Congruence CEO

New Or­biMed-backed biotech aims to repli­cate Ver­tex's wild­ly suc­cess­ful cys­tic fi­bro­sis pills in oth­er dis­eases

A new biotech aim­ing to tack­le pro­tein mis­fold­ing has land­ed a sub­stan­tial Se­ries A from some blue-chip in­vestors.

Con­gru­ence Ther­a­peu­tics burst on­to the scene Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.